Rabin Martin scoped and designed programs to support early access to a forthcoming dengue vaccine for vulnerable populations in endemic countries, with the goal of including the vaccine in National Immunization Programs.
Dengue is the most common mosquito-borne disease in the world and causes an estimated 390 million infections and 20,000 deaths each year. Asia and Latin America are disproportionately affected. This dengue vaccine is a promising new tool to deliver substantial public health benefits across the world.
The client has stated an ambitious access approach for its dengue vaccine – to improve health outcomes by providing early access to vulnerable populations regardless of an individual’s ability to afford the vaccine.
In support of this approach, Rabin Martin supported the client in laying the groundwork for a dengue vaccine access program:
- Synthesized best practices in designing and implementing access programs
- Identified select countries to scope programs based on public health need and potential for national scale up
- Developed initial program designs and identified potential partners for collaboration
- Consulted global experts on key considerations for program execution, including how the company can address potential barriers to public adoption of the vaccine
Impact
The program has been embedded into the company’s broader vaccine launch strategy. A key component of this effort – targeted to low-income, vulnerable populations – is generating country-specific evidence around vaccine adoption and delivery, with the goal of supporting scale up and incorporation of the vaccine into countries’ national immunization programs.
See more of our work
and impact
Rabin Martin consultants share expert insights on what’s emerging, what’s working, and what’s needed to improve health outcomes, access, and equity.
View all case studies